Home › Compound Library › Ziprasidone (Geodon)

Ziprasidone (Geodon)

Antipsychoticprescriptionoral · inferred

Benzisothiazolyl piperazine atypical antipsychotic with the most weight-neutral profile among older atypicals. Potent 5-HT2A/D2 antagonist with unique 5-HT/NE reuptake inhibition. Must be taken with food (>=500 calories), bioavailability increases from 30% to 60% with food. QTc prolongation warning, though clinical significance debated. Metabolized by CYP3A4 and aldehyde oxidase.

Projected serum levels — 40 mg, twice daily

Ziprasidone (Geodon)
Ziprasidone (Geodon) modeled serum levels, 40 mg twice daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 12.5 25 37.5 50 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1
Ziprasidone (Geodon) modeled serum levels with a loading dose of 63.0 mg, then 40 mg twice daily The first dose is larger so levels approach steady state faster. 0 12.5 25 37.5 50 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 40 mg twice daily (oral).

Loading schedule: 63.0 mg on day 1, then 40 mg twice daily — reaching therapeutic levels sooner.

Modeled steady state after ~1 days: peak ≈ 25.4 mg, trough ≈ 13.0 mg body load. Population-based estimate over 15 days for a 40 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Antipsychotic
Route modeled
Oral
Model confidence
inferred
Half-life
7 h
Common dose
40 mg
Suggested maximum
160 mg/day
Reference dose range
20–160 mg (single dose)
Suggested cadence
twice daily
Validated against
40 mg oral — Cmax 0.15 mg/L at 4 h

Documented interactions

  • danger
    1P-LSD (1-Propionyl-LSD) + Ziprasidone (Geodon) Serotonin risk

    1P-LSD (1-Propionyl-LSD) and Ziprasidone (Geodon) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    25I-NBOMe + Ziprasidone (Geodon) Serotonin risk

    25I-NBOMe and Ziprasidone (Geodon) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-I (2,5-Dimethoxy-4-iodophenethylamine) + Ziprasidone (Geodon) Serotonin risk

    2C-I (2,5-Dimethoxy-4-iodophenethylamine) and Ziprasidone (Geodon) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + Ziprasidone (Geodon) Serotonin risk

    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and Ziprasidone (Geodon) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    3-MeO-PCP (3-Methoxyphencyclidine) + Ziprasidone (Geodon) Serotonin risk

    3-MeO-PCP (3-Methoxyphencyclidine) and Ziprasidone (Geodon) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    4-AcO-DMT (Psilacetin) + Ziprasidone (Geodon) Serotonin risk

    4-AcO-DMT (Psilacetin) and Ziprasidone (Geodon) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

Serum checks 356 modeled interaction pairings for ziprasidone (geodon) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Ziprasidone versus olanzapine in the treatment of schizophrenia: 28-week double-blind extension (CAFE trial) Stroup TS et al. · American Journal of Psychiatry, 2006 DOI

    Head-to-head RCT finding ziprasidone comparable to olanzapine for schizophrenia efficacy but with significantly less weight gain (mean 0.3 kg vs 3.7 kg) and superior metabolic profile.

  2. Ziprasidone: pharmacokinetics and clinical implications Miceli JJ et al. · Clinical Pharmacokinetics, 2000 DOI

    PK review establishing ziprasidone half-life of 6-7 hours, food-dependent bioavailability (doubles with >=500 kcal meal), dual CYP3A4/aldehyde oxidase metabolism, and linear pharmacokinetics up to 80 mg BID.

2 published studies referenced in the app, each with a plain-language summary.